FDA Grants Extra Review Time for Leadless Pacemaker Patent
Published Date: 6/16/2025
Notice
Summary
The FDA has officially set the review period for the AVEIR VR Leadless System, a cool medical device. This means the company can ask for extra patent time to protect their invention. If you’re in the medical or patent world, watch for this chance to extend patent rights and keep innovation rolling!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Patent Extension Eligible for AVEIR
The FDA has set the regulatory review period for the AVEIR VR Leadless System. Because of that determination, the company (or the patent owner) can apply to the U.S. Patent and Trademark Office (USPTO) to extend the patent term that covers this medical device.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in